Pharmakologische Konzepte zur Behandlung der Adipositas – ein therapeutischer Irrweg?

Schlüsselwörter

Adipositas - Orlistat - Rimonabant

Keywords

obesity - orlistat - rimonabant

Literatur

• 1 Batterham R L, Cohen M A, Ellis S M. et al . Inhibition of food intake in obese subjects by peptide YY3 – 36.  N Engl J Med. 2003;  349 941-948
• 2 Chaudhri O B, Wynne K, Bloom S R. Can gut hormones control appetite and prevent obesity?.  Diabetes Care. 2008;  31 Suppl 2 S284-289
• 3 Day J W, Ottaway N, Patterson J T. et al . A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.  Nat Chem Biol. 2009;  5 749-757
• 4 Food and Drug Administration. FDA Issues Complete Response Letter for Lorcaserin New Drug Application 2010. http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977 letzter Zugriff 4.7.2011
• 5 Field B C, Chaudhri O B, Bloom S R. Bowels control brain: gut hormones and obesity.  Nat Rev Endocrinol. 2010;  6 444-453
• 6 Hauner H, Buchholz G, Hamann A. et al .Evidenzbasierte Leitlinie Therapie und Prävention der Adipositas. 2007. http://www.dge.de/pdf/ll/Adipositas-Leitlinie-2007.pdf letzter Zugriff 28.6.2010
• 7 Hollander P A, Elbein S C, Hirsch I B. et al . Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.  Diabetes Care. 1998;  21 1288-1294
• 8 Inui A, Asakawa A, Bowers C Y. et al . Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ.  Faseb J. 2004;  18 439-456
• 9 Li Z, Maglione M, Tu W. et al . Meta-analysis: pharmacologic treatment of obesity.  Ann Intern Med. 2005;  142 532-546
• 10 Roth J D, Roland B L, Cole R L. et al . Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies.  Proc Natl Acad Sci U S A. 2008;  105 7257-7262
• 11 Rucker D, Padwal R, Li S K. et al . Long term pharmacotherapy for obesity and overweight: updated meta-analysis.  Brit Med J. 2007;  335 1194-1199
• 12 Schindler C, Kirch W. Eine Lehrstunde zur Arzneimittelentwicklung am Beispiel Rimonabant?.  Dtsch Med Wochenschr. 2010;  135 2064
• 13 Torp-Pedersen C, Caterson I, Coutinho W. et al . Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.  Eur Heart J. 2007;  28 2915-2923
• 14 World Health Organization .Obesity and overweight. WHO fact sheet N 311, March 2011. 
• 15 Wright S M, Aronne L J. Obesity in 2010: the future of obesity medicine: where do we go from here?.  Nat Rev Endocrinol. 2011;  7 69-70